tocilizumab

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved Reliance Life Science’s Phase III clinical trial protocol of immunosuppressive Tocilizumab with some changes in exclusion criteria. This came after the firm presented the proposal to conduct a Phase III clinical trial titled “A prospective, multicenter, randomized, […] More